Treatment Algorithms in Systemic Lupus Erythematosus
Authors:
- 16 March 2015
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 67 (9) , 1237-1245
Abstract
Objective: To establish agreement on systemic lupus erythematosus (SLE) treatment.Methods: SLE experts (n = 69) were e‐mailed scenarios and indicated preferred treatments. Algorithms were constructed and agreement determined (≥50% respondents indicating ≥70% agreement).Results: Initially, 54% (n = 37) responded suggesting treatment for scenarios; 13 experts rated agreement with scenarios. Fourteen of 16 scenarios had agreement as follows: discoid lupus: first‐line therapy was topical agents and hydroxychloroquine and/or glucocorticoids then azathioprine and subsequently mycophenolate (mofetil); uncomplicated cutaneous vasculitis: initial treatment was glucocorticoids ± hydroxychloroquine ± methotrexate, followed by azathioprine or mycophenolate and then cyclophosphamide; arthritis: initial therapy was hydroxychloroquine and/or glucocorticoids, then methotrexate and subsequently rituximab; pericarditis: first‐line therapy was nonsteroidal antiinflammatory drugs, then glucocorticoids with/without hydroxychloroquine, then azathioprine, mycophenolate, or methotrexate and finally belimumab or rituximab, and/or a pericardial window; interstitial lung disease/alveolitis: induction was glucocorticoids and mycophenolate or cyclophosphamide, then rituximab or intravenous gamma globulin (IVIG), and maintenance followed with azathioprine or mycophenolate; pulmonary hypertension: glucocorticoids and mycophenolate or cyclophosphamide and an endothelin receptor antagonist were initial therapies, subsequent treatments were phosphodiesterase‐5 inhibitors and then prostanoids and rituximab; antiphospholipid antibody syndrome: standard anticoagulation with/without hydroxychloroquine, then a thrombin inhibitor for venous thrombosis, versus adding aspirin or platelet inhibition drugs for arterial events; mononeuritis multiplex and central nervous system vasculitis: first‐line therapy was glucocorticoids and cyclophosphamide followed by maintenance with azathioprine or mycophenolate, and then rituximab, IVIG, or plasmapheresis; and serious lupus nephritis: first‐line therapy was glucocorticoids and mycophenolate, then cyclophosphamide then rituximab.Conclusion: We established variable agreement on treatment approaches. For some treatment decisions there was good agreement between experts even if no randomized controlled trial data were available.Keywords
This publication has 52 references indexed in Scilit:
- Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND studyBlood, 2013
- Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)British Journal of Haematology, 2012
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisAnnals of the Rheumatic Diseases, 2012
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals of the Rheumatic Diseases, 2012
- Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: A meta‐analysisNephrology, 2012
- American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care & Research, 2012
- Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trialJournal of the American Academy of Dermatology, 2011
- Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical TrialAmerican Journal of Kidney Diseases, 2011
- Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune studyLupus, 2010
- Resistant discoid lupus erythematosus of palms and soles: Successful treatment with azathioprineJournal of the American Academy of Dermatology, 1988